ICOP-Pharm: could the new paradigm bridge a gap in evidence raised by 2022 ESC guidelines on cardio-oncology?
- 2 December 2022
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (11) , 912-915
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Cardiovascular drug interventions in the cardio-oncology clinic by a cardiology pharmacist: ICOP-Pharm studyFrontiers in Cardiovascular Medicine, 2022
- INTERVENTIONS BY THE CARDIOLOGY CLINICAL PHARMACIST AT THE CARDIO-ONCOLOGY CLINICJACC, 2022
- Perceptions of the Cardiologists and Oncologists: Initial Step for Establishing Cardio-Oncology ServiceFrontiers in Cardiovascular Medicine, 2021
- Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyEuropean Journal of Heart Failure, 2020
- Clinical Experience of Patients Referred to a Multidisciplinary Cardio-Oncology Clinic: An Observational Cohort StudyCurrent Oncology, 2019
- Activity and Outcomes of a Cardio-Oncology Service in the United Kingdom—A Five-Year ExperienceEuropean Journal of Heart Failure, 2018
- Effectiveness of pharmacist’s intervention in the management of cardiovascular diseasesOpen Heart, 2018
- Validity of medical history taken by pharmacists using a medical history taking toolJournal of General and Family Medicine, 2017